About: Suppression of experimental autoimmune myasthenia gravis by nasal administration of acetylcholine receptor

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Suppression of experimental autoimmune myasthenia gravis by nasal administration of acetylcholine receptor Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 April 1995

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована у квітні 1995 (uk) im April 1995 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu n'abril de 1995 (ast) scientific article published on 01 April 1995 (en)
publication date	wds:Q71690385-2CD9C279-3A40-4AB2-BFC3-093E94D77553
publication date	1995-04-01 00:00:00Z (xsd:dateTime)
author name string	wds:Q71690385-0A5F5E48-714A-44C6-8FB1-60262DD563B6 wds:Q71690385-1DDEF453-95C7-4235-88C4-6CC212E91B40 wds:Q71690385-2CC56B98-2E70-4197-B06A-F5851EF4EC91 wds:Q71690385-3877E4BD-D81C-4A13-9078-408A4B028ECB wds:Q71690385-4F7B7406-80B8-4813-ABF6-C1863B867D06 wds:Q71690385-AF50082D-1910-4B65-AE47-F58ED9FF18F7
author name string	J Link H Link G X Zhang T Olsson B G Xiao C G Ma
rdfs:label	Suppression of experimental autoimmune myasthenia gravis by nasal administration of acetylcholine receptor (en) Suppression of experimental autoimmune myasthenia gravis by nasal administration of acetylcholine receptor (nl)
skos:prefLabel	Suppression of experimental autoimmune myasthenia gravis by nasal administration of acetylcholine receptor (en) Suppression of experimental autoimmune myasthenia gravis by nasal administration of acetylcholine receptor (nl)
name	Suppression of experimental autoimmune myasthenia gravis by nasal administration of acetylcholine receptor (en) Suppression of experimental autoimmune myasthenia gravis by nasal administration of acetylcholine receptor (nl)
title	wds:Q71690385-1FDB5F15-F795-414E-A19F-E6C102FF38C5
title	Suppression of experimental autoimmune myasthenia gravis by nasal administration of acetylcholine receptor (en)
page(s)	wds:Q71690385-4A9CACAA-D35E-47B2-A250-3EFEA73DCFEA
page(s)	51-60
instance of	wds:Q71690385-5123BC10-B27E-40CF-85AF-7D6EE9F7CBD1
instance of	scholarly article
main subject	wds:Q71690385-4AAE8916-1605-41D7-9AB9-E1CCDBF6C230
main subject	myasthenia gravis
PubMed ID	wds:Q71690385-E0A21168-37CD-41E2-A716-2593B0394D8C
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/7537280
PubMed ID	7537280
published in	wds:Q71690385-19B4857E-FB0C-4E74-8D40-F086E1B313FE
published in	Journal of Neuroimmunology
issue	wds:Q71690385-FC3990B3-DCC7-47EE-8443-3AA4C7EB9BED
volume	wds:Q71690385-47D9E474-347E-4BAD-B49A-6ADD2A03D530
issue	1
volume	58
DOI	wds:Q71690385-C26002A6-F0EE-4C6B-8F93-88AE8069B1D0
DOI	http://dx.doi.org/10.1016/0165-5728(94)00187-S
DOI	10.1016/0165-5728(94)00187-S
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q71690385
is cites work of	Antigen-specific modulation of experimental myasthenia gravis: nasal tolerization with recombinant fragments of the human acetylcholine receptor alpha-subunit Prevention of experimental myasthenia gravis by nasal administration of synthetic acetylcholine receptor T epitope sequences Oral tolerance: immune mechanisms and treatment of autoimmune diseases Suppression of antigen-specific T- and B-cell responses by intranasal or oral administration of recombinant bet v 1, the major birch pollen allergen, in a murine model of type I allergy Dendritic cells and immune responses to orally administered antigens Nicotinic acetylcholine receptors in health and disease Nasal lymphoid tissue, intranasal immunization, and compartmentalization of the common mucosal immune system Intranasal immunization with heat shock protein 60 induces CD4(+) CD25(+) GARP(+) and type 1 regulatory T cells and inhibits early atherosclerosis Suppression of ongoing experimental myasthenia by oral treatment with an acetylcholine receptor recombinant fragment. The nature of the active suppression of responses associated with experimental autoimmune myasthenia gravis by a dual altered peptide ligand administered by different routes Oral tolerance: mechanisms and therapeutic applications. Both CD4+ and CD8+ T cells are essential to induce experimental autoimmune myasthenia gravis Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23) Therapeutic vaccines in autoimmunity Nasal administration of myelin basic protein prevents relapsing experimental autoimmune encephalomyelitis in DA rats by activating regulatory cells expressing IL-4 and TGF-beta mRNA. Dose-dependent mechanisms relate to nasal tolerance induction and protection against experimental autoimmune encephalomyelitis in Lewis rats CD4+LAP + and CD4 +CD25 +Foxp3 + regulatory T cells induced by nasal oxidized low-density lipoprotein suppress effector T cells response and attenuate atherosclerosis in ApoE-/- mice Intranasal delivery of FSD-C10, a novel Rho kinase inhibitor, exhibits therapeutic potential in experimental autoimmune encephalomyelitis Mechanism of nasal tolerance induced by a recombinant fragment of acetylcholine receptor for treatment of experimental myasthenia gravis Oral administration of an immunodominant T-cell epitope downregulates Th1/Th2 cytokines and prevents experimental myasthenia gravis Current and emerging treatments for the management of myasthenia gravis Specific immunotherapy of experimental myasthenia gravis by a novel mechanism Myasthenia gravis and the tops and bottoms of AChRs: antigenic structure of the MIR and specific immunosuppression of EAMG using AChR cytoplasmic domains Total dose and frequency of administration critically affect success of nasal mucosal tolerance induction Immunological treatment of autoimmune diseases. Nasal tolerance in experimental autoimmune myasthenia gravis (EAMG): induction of protective tolerance in primed animals Linomide suppresses both Th1 and Th2 cytokines in experimental autoimmune myasthenia gravis Animal models of myasthenia gravis: utility and limitations Standardization of the experimental autoimmune myasthenia gravis (EAMG) model by immunization of rats with Torpedo californica acetylcholine receptors--Recommendations for methods and experimental designs Advances in autoimmune myasthenia gravis management Nasal administration of cardiac myosin suppresses autoimmune myocarditis in mice Autoreactive T cell responses and cytokine patterns reflect resistance to experimental autoimmune myasthenia gravis in Wistar Furth rats. Preventive administration of Mycobacterium tuberculosis 10-kDa heat shock protein (hsp10) suppresses adjuvant arthritis in Lewis rats Is pathogenic humoral autoimmunity a Th1 response? Lessons from (for) myasthenia gravis A Novel Approach to Reinstating Tolerance in Experimental Autoimmune Myasthenia Gravis Using a Targeted Fusion Protein, mCTA1-T146. Nasal administration of multiple antigens suppresses experimental autoimmune myasthenia gravis, encephalomyelitis and neuritis Complexities of applying nasal tolerance induction as a therapy for ongoing relapsing experimental autoimmune encephalomyelitis (EAE) in DA rats Oral tolerance: elucidation of mechanisms and application to treatment of autoimmune diseases Induction of oral tolerance to the acetylcholine receptor for treatment of myasthenia gravis Current and future therapies for myasthenia gravis Synthetic peptides fail to induce nasal tolerance to experimental autoimmune myasthenia gravis. Vaccines against myasthenia gravis. Oral tolerance and the treatment of rheumatoid arthritis Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics
is cites work of	wds:Q37376234-9733179C-D023-4CB0-9C9C-7131E3EEB3FB wds:Q41834495-1F64A7E4-E8C8-45E4-9F74-7B744FB2A03A wds:Q73128589-074A0F19-AB71-426F-9DA1-CF01E6338FD2 wds:Q64044796-C877FD2C-5C87-408B-B63B-17AD62228BE9 wds:Q73226922-4339F6D8-87D2-4385-A54B-A9FEFE52DD8E wds:Q77969613-B816AF7D-0AF0-42BC-9F4D-FDC174A9CAD3 wds:Q33901936-8CF15B4F-FCD2-462F-A244-7894D1F083F3 wds:Q36055982-8FEE95DC-384C-46C2-8B51-082CDEBDBE38 wds:Q35861944-84839546-4654-4ACC-AC24-ECF9DECE5FF8

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 171 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software